Ars Pharmaceuticals News Today

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) insider Sarina Tanimoto sold 100,000 shares of the company’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $9.28, for a total transaction of $928,000.00. Following the completion of the transaction, the insider now directly owns 1,647,447 shares in […]

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) insider Sarina Tanimoto sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $9.28, for a total transaction of $928,000.00. Following the transaction, the insider now directly owns 1,647,447 shares in the company, valued […]

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) insider Sarina Tanimoto sold 2,343 shares of the stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $9.02, for a total value of $21,133.86. Following the completion of the transaction, the insider now owns 1,745,082 shares of the company’s […]

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) shares reached a new 52-week high during trading on Tuesday . The stock traded as high as $9.75 and last traded at $9.73, with a volume of 978686 shares trading hands. The stock had previously closed at $9.13. Analyst Ratings Changes Several analysts have issued reports on […]

ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) was upgraded by equities research analysts at William Blair from a “market perform” rating to an “outperform” rating in a report released on Tuesday, MarketBeat Ratings reports. Separately, Wedbush increased their price target on ARS Pharmaceuticals from $5.00 to $13.00 and gave the stock an “outperform” rating in […]

ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) was upgraded by equities research analysts at William Blair from a “market perform” rating to an “outperform” rating in a report released on Tuesday, MarketBeat Ratings reports. Separately, Wedbush increased their price target on ARS Pharmaceuticals from $5.00 to $13.00 and gave the stock an “outperform” rating in […]

ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) was upgraded by William Blair from a “market perform” rating to an “outperform” rating in a research note issued to investors on Tuesday, MarketBeat.com reports. Separately, Wedbush increased their target price on ARS Pharmaceuticals from $5.00 to $13.00 and gave the company an “outperform” rating in a research […]

Biopharmaceutical company ARS Pharmaceuticals, Inc. (SPRY) announced Friday that the U.S. Food and Drug Administration (FDA) has scheduled a Type A meeting to discuss the contents of a Complete Response Letter (CRL) previously issued regarding its new drug application (NDA) for neffy (epinephrine nasal spray) for the treatment of allergic reactions (Type I), including anaphylaxis.

By Colin Kellaher ARS Pharmaceuticals will meet later this month with the U.S. Food and Drug Administration to discuss the agency's rejection of the...

Scopia Management disclosed a large stake in streaming and broadband-services firm Harmonic. Gamco Investors raised its stake in digital-games maker SciPlay.